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Abstract
AIM: To investigate the benefits of insulin like growth 
factor-1 (IGF-1) supplementation to serum-free institut 
georges lopez-1 (IGL-1)® solution to protect fatty liver 
against cold ischemia reperfusion injury. 
METHODS: Steatotic livers were preserved for 24 h in 
IGL-1® solution supplemented with or without IGF-1 and 
then perfused “ex vivo” for 2 h at 37℃. We examined the 
effects of IGF-1 on hepatic damage and function (trans-
aminases, percentage of sulfobromophthalein clearance 
in bile and vascular resistance). We also studied other 
factors associated with the poor tolerance of fatty livers 
to cold ischemia reperfusion injury such as mitochondrial 
damage, oxidative stress, nitric oxide, tumor necrosis 
factor-α (TNF-α) and mitogen-activated protein kinases.
RESULTS: Steatotic livers preserved in IGL-1® solution 
supplemented with IGF-1 showed lower transaminase 
levels, increased bile clearance and a reduction in vascular 
resistance when compared to those preserved in IGL-1® 
solution alone. These benefits are mediated by activation 
of AKT and constitutive endothelial nitric oxide synthase 
(eNOS), as well as the inhibition of inflammatory cyto-
kines such as TNF-α. Mitochondrial damage and oxidative 
stress were also prevented.
CONCLUSION: IGL-1® enrichment with IGF-1 increased 
fatty liver graft preservation through AKT and eNOS acti-
vation, and prevented TNF-α release during normother-
mic reperfusion.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
One of  the major challenges in liver transplantation is to 
increase the use of  marginal organs. Steatotic, or fatty, liv-
ers are increasingly transplanted, in spite of  the associated 
risk of  graft dysfunction or non-function as a result of  
cold ischemia reperfusion injury (IRI)[1,2]. Steatotic livers 
show poor tolerance to IRI due to severe mitochondrial 
damage, impaired energy metabolism[3], increased reactive 
oxygen species (ROS) and release of  inflammatory cyto-
kines such as tumour necrosis factor-α (TNF-α), which 
impairs microcirculation[4,5]. All these factors render stea-
totic livers more vulnerable to cold IRI. 
Liver preservation is a crucial step in maintaining graft 
quality after prolonged ischemic periods, especially steatotic 
livers. University of  Wisconsin (UW) is the most widely used 
serum-free preservation solution for transplantation but 
it does not fully protect liver grafts during prolonged stor-
age[6-8]. Recently, the new institut georges lopez-1 (IGL-1)® 
solution has been proposed as an effective alternative to UW 
in clinical kidney transplantation[9,10], and in experimental or-
thotopic liver transplantation models[11,12]. IGL-1® solution is 
characterized by inversion of  K+ and Na+ concentrations in 
the UW solution and contains polyethylene glycol as osmot-
ic support instead of  HES. In addition, we have previously 
demonstrated that IGL-1® is more suitable than UW solu-
tion for fatty liver preservation[13]. Its benefits are associated 
in part, with the prevention of  oxidative stress and its capac-
ity to generate nitric oxide (NO)[13]. NO is a vasodilator with 
anti-inflammatory properties that prevents microcirculatory 
alterations[5,13] and the release of  pro-inflammatory cyto-
kines, such as TNF-α, during IRI[14-16].
Insulin like growth factor-1 (IGF-1) is a vascular pro-
tective factor that is mainly synthesized and released by 
the liver[17,18]. We have recently reported impaired synthesis 
of  IGF-1 in steatotic livers subjected to warm IRI, and 
that exogenous administration of  recombinant IGF-1 
reduced IRI in steatotic livers[18]. IGF-1 prevents oxidative 
stress[17] and induces NO generation by eNOS activation, 
as a consequence of  AKT kinase phosphorylation[19,20]. 
Several trophic factors (TF), including IGF-1, have 
been added to UW solution in an attempt to improve the 
survival of  pig orthotopic liver allografts after 18 h of  
cold storage[21]. In vascular endothelial cells, the benefits 
of  TF supplementation are associated with limitation of  
mitogen-activated protein kinase (MAPK) activities after 
cold ischemia/rewarming injury[22]. 
Taking this into account, we explored the effects of  
the addition of  IGF-1 to IGL-1® solution on fatty liver 
preservation during cold IRI. We examined the mecha-
nisms responsible for such effects, including AKT phos-
phorylation and NO generation, and the prevention of  
ROS production and TNF-α release after reperfusion. 
These latter factors have been implicated in the poor tol-
erance of  steatotic livers to cold IRI. 
MATERIALS AND METHODS
Animals and liver procurement
Isolated perfused rat liver was used to evaluate hepatic 
function in isolation from the influence of  other organ 
systems (undefined plasma constituents and neural/hor-
monal effects). Hepatic architecture, microcirculation 
and bile production were preserved in this experimental 
model, as previously reported[23]. Homozygous obese (Ob) 
Zucker rats, aged 16-18 wk were purchased from Iffa-
Credo (L’Abresle, France) and were housed at 22℃[23]. 
All procedures were performed under isoflurane inhala-
tion anaesthesia. Experiments were conducted according 
to European Union regulations for animal experiments 
(Directive 86/609 CEE).
Liver procurement and experimental groups
The surgical technique was performed as previously re-
ported[23,24]. After cannulation of  the common bile duct, 
the portal vein was isolated and the splenic and gastro-
duodenal veins were ligated. All animals were randomly 
distributed into groups as described below. The steatotic 
livers were flushed and preserved in cold IGL-1® solution 
for 24 h with or without the addition of  IGF-1 (10 μg/L), 
as described elsewhere[21,22,25]. 
All animals were randomized according to the experi-
mental protocols, as follows.
Cold storage: After 24 h of  cold storage at 4℃, livers 
from 8 Zucker rats preserved in IGL-1 solution with (IGL-1 
+ IGF-1) or without IGF-1 were flushed with Ringer’s 
lactate solution. Control livers (Cont 1) from 8 Zucker rats 
(Ob) were flushed with Ringer’s lactate solution at room 
temperature immediately after laparotomy via the portal 
vein without cold storage. Aliquots of  the effluent flush 
were sampled for measurements of  cumulative AST and 
ALT after 24 h cold storage.
Cold storage and reperfusion: Briefly, after 24 h cold 
storage at 4℃, livers from 8 Zucker rats (Ob) preserved in 
IGL-1 and IGL-1 + IGF-1 solutions were subjected to 2 h 
reperfusion at 37℃, as previously reported[13,24]. Control 
livers (Cont 2) from 8 Zucker rats (Ob) were flushed with 
Ringer’s lactate at room temperature and immediately per-
fused ex vivo without ischemic preservation.
Transaminase assay
Hepatic injury was assessed in terms of  transaminase lev-
els with commercial kits from RAL (Barcelona, Spain)[26]. 
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Briefly, 200 μL of  effluent perfusate were added to the 
substrate provided by the commercial kit and then alanine 
aminotransferase (ALT)/aspartate aminotransferase (AST) 
levels were determined at 365 nm with a UV spectrometer 
and calculated following the supplier’s instructions. 
Hepatic clearance
As with bile output, hepatic clearance was considered as 
another parameter of  hepatic function. Thirty minutes 
after the onset of  perfusion (t30), 1 mg of  sulfobromoph-
thalein (BSP) (Sigma, Madrid, Spain) was added to the per-
fusate. The concentration of  BSP in bile samples (t120) was 
measured at 580 nm with a UV-visible spectrometer. Bile 
BSP excretion was expressed as a percentage of  perfusate 
content (t120 bile/t30 perfusate*100)[23].
Vascular resistance 
Liver circulation was assessed by measuring perfusion flow 
rate and vascular resistance. Perfusion flow rate was as-
sessed continuously throughout the reperfusion period and 
expressed as mL/min per gram of  liver. Vascular resistance 
was defined as the ratio of  portal venous pressure to flow 
rate and expressed in mmHg/min per gram of  liver/mL[26].
Glutamate dehydrogenase activity
Glutamate dehydrogenase (GLDH) was used as an in-
direct measure of  mitochondrial damage. GLDH was 
measured in the perfusate as described elsewhere[26].
Lipid peroxidation assay
Lipid peroxidation in liver was used as an indirect mea-
sure of  the oxidative injury induced by ROS. Lipid per-
oxidation was determined by measuring the formation 
of  malondialdehyde (MDA) with the thiobarbiturate 
reaction[13]. 
Determination of nitrite and nitrate 
NO production in liver was determined by tissue accu-
mulation of  nitrite and nitrate[13]. 
Western blotting analysis of eNOS, AKT, P38 and ERK 1/2 
Liver tissue was homogenized as previously described and 
proteins were separated by SDS-PAGE and transferred to 
PVDF membranes[27-29]. Membranes were immunoblot-
ted using the following antibodies: eNOS (Transduction 
Laboratories, Lexington, KY, USA), total and phosphory-
lated AKT, total and phosphorylated P38, and total and 
phosphorylated ERK 1/2 (Cell Signaling, Beverly, MA, 
USA) and β-actin (Sigma Chemical, St. Louis, MO, USA). 
Signals were detected by the enhanced chemilumines-
cence kit (Bio-Rad Laboratories, Hercules, CA, USA) and 
quantified by scanning densitometry as previously de-
scribed[26,28].
TNF-α determination
Perfusate TNF-α levels were measured after 120 min of  
reperfusion using a commercial immunoassay kit for rat 
TNF-α from Biosource (Camarillo, CA, USA)[30,31]. 
Statistical analysis
Data are expressed as means ± SE, and were compared 
statistically by variance analysis, followed by the Student-
Newman-Keuls test (Graph Pad Prism software). P < 0.05 
was considered significant.
RESULTS
Protective effect of IGF-1 against liver injury and function 
As shown in Figure 1A and B, the AST and ALT levels ob-
served for steatotic livers preserved for 24 h at 4℃ in IGL-1® 
solution confirmed their poor tolerance to cold ischemia 
injury. IGF-1 addition prevented AST/ALT release from 
steatotic livers when compared with IGL-1 alone.
Similar AST/ALT profiles were obtained when fatty 
livers were subjected to normothermic reperfusion for 
30 and 120 min, respectively. Reduced AST/ALT levels 
were observed when IGL-1 was enriched with IGF-1 
(Figure 1C and D). Similar profiles were seen for 60 and 
90 min of  reperfusion (data not shown).
The mechanisms by which IGF-1 protects fatty livers 
against the harmful consequences of  cold I/R damage 
were also investigated. For this reason, liver function was 
evaluated by the alterations in BSP clearance and vascu-
lar resistance, respectively. A reduction in BSP clearance 
was found in IGL-1 solution when compared to Cont 2. 
The highest BSP clearance in bile was observed after 2 h 
of  normothermic reperfusion when IGF-1 was present 
(Figure 2A).
Vascular resistance was increased by IGL-1 solution 
(Figure 2B), but this was reversed by the addition of  IGF-1. 
These alterations in vascular resistance were also seen in all 
groups at 30 and 120 min of  reperfusion (Figure 2B). 
Beneficial effects of IGF-1 on AKT and NO after 
reperfusion
In order to explore whether the beneficial effects of  IGF-1 
in IGL-1 solution are associated with other protective cell 
signalling involved in the protective mechanisms against 
IRI, we evaluated the changes in AKT and NO levels. As 
shown in Figure 3, IGF-1 increased AKT phosphorylation 
when compared to IGL-1 alone and Cont 2, respectively 
(Figure 3A). This was concomitant with a significant gen-
eration of  NO, as revealed by the nitrites/nitrates levels, as 
well as eNOS activation (Figure 3B and C). 
Role of IGF-1 on liver oxidative stress, mitochondrial 
damage and TNF-α release after reperfusion
In order to examine the relationship between the param-
eters studied and others associated with the poor toler-
ance of  fatty livers to reperfusion injury, we evaluated lipid 
peroxidation (MDA) and mitochondrial damage (GLDH). 
Steatotic livers preserved in IGL-1 showed significant 
MDA augments when compared to Cont 2. These increas-
es were significantly prevented by the addition of  IGF-1 
(Figure 4A). In accordance with this, IGF-1 also diminished 
liver mitochondrial damage, as shown by the reduction in 
GLDH (Figure 4B). These beneficial effects of  IGF-1 were 
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also accompanied by a significant reduction in pro-inflam-
matory cytokine TNF-α level when compared to IGL-1 
alone after 2 h normothermic reperfusion (Figure 4C).
Effects of IGF-1 on p-P38 and p-ERK MAPKs after 
reperfusion
Finally, we examined the effects of  IGL-1 with and without 
IGF-1 on P38 and ERK 1/2 MAPKs, whose activation is 
closely related with hypothermic conditions. Figure 5 shows 
increased phosphorylation of  ERK 1/2 and P38 MAPK 
in IGL-1 solution when compared to Cont 2, but again this 
increase was offset by the addition of  IGF-1.
DISCUSSION
IGF-1 is a 70-amino-acid polypeptide, mainly synthesized 
by the liver, with protective effects against IRI in a variety 
of  tissues[32-35], including the liver[18]. We recently reported 
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that IGF-1 protects steatotic livers subjected to warm 
IRI, but its role in fatty liver preservation has been poorly 
investigated[18]. For this reason, we explored the effect of  
IGF-1 supplementation of  serum free IGL-1® solution, 
which has been shown to protect fatty livers against cold 
IRI[13]. We used the concentration of  IGF-I (10 μg/L) 
according to previous studies carried out in different ex-
perimental models. In these studies, IGF-I it was used to 
supplement UW solution in dog kidney transplantation, as 
well as, primary canine kidney tubule and human umbilical 
vein endothelial cell cultures[21,22,25,36]. The results reported 
here show that the addition of  IGF-1 to IGL-1® solution 
significantly improved fatty liver preservation, as evi-
denced by the reduction in AST/ALT levels. These results 
are consistent with previous reports by other authors, who 
demonstrated that the addition of  TF to UW solution im-
proves the survival of  orthotopic liver allografts[21]. 
BSP clearance in bile is a useful tool for assessing liver 
function after prolonged cold ischemia[23,24]. It is well es-
tablished that complications in biliary structures appear in 
more than 25% of  liver transplant recipients. The increases 
in BSP clearance observed in IGL-1 + IGF-1 solution re-
vealed that IGF-1 supplementation enhances steatotic graft 
function. 
Steatosis is the result of  intracytoplasmic fat accumula-
tion, which is associated with an increase in hepatocellular 
volume, induced distortion and narrowing of  sinusoids 
with a reduction in the luminal diameter by up to 50% 
when compared to normal liver[5]. This provokes severe 
alterations in hepatic blood flow and microcirculation, and 
prevents appropriate revascularization of  the graft. The 
benefits of  the use of  IGL-1® solution for fatty liver pres-
ervation are associated with its capacity to generate NO[13], 
a potent vasodilator involved in the regulation of  hepatic 
microcirculation, through eNOS activation, as previously 
reported by us[24]. Moreover, it has been established that 
IGF-1 up-regulates eNOS activity by interacting with a ty-
rosine kinase membrane receptor which activates the AKT 
signalling pathway[19,37,38]. The results of  the present study 
show that IGF-1 increases AKT phosphorylation and en-
hance eNOS activation induced by IGL-1® alone. This in 
turn induces NO generation, which reduces vascular resis-
tance following reperfusion. This is in line with several re-
ported studies demonstrating that a low concentration of  
eNOS-derived NO maximizes blood perfusion, promotes 
cell survival and protects the liver against IRI[39]. In con-
trast, the sustained presence of  iNOS-derived NO might 
become detrimental by increasing toxic reactive oxygen 
species, thus leading to liver injury[39-41]. In our experimen-
tal model, the benefits of  NO were not associated with 
iNOS activation (data not show). Moreover, other studies 
demonstrate that while increasing e-NOS, IGF-1 inhibits 
inducible NO[19,42].
It is clear that fatty accumulation resulting from ste-
atosis induces ultra-structural and biochemical changes in 
liver mitochondria[43,44], which may render these organelles 
intrinsically more susceptible to IRI injury. Given that mito-
chondria are the main sites of  ROS production in IRI, the 
increased oxidative stress observed in steatotic livers after 
cold IRI could be attributed to mitochondrial damage. It is 
well known that IGF-1 prevents mitochondrial damage and 
oxidative stress following IRI[17,33,34]. Our results indicate 
that the addition of  IGF-1 to IGL-1® preservation solution 
increases liver mitochondria protection, and prevents ROS 
generation associated with reperfusion injury. 
Vairetti et al[45] using the same “ex vivo” experimental 
model, have shown that TNF-α is released when fatty 
livers are subjected to cold ischemia reperfusion. In our 
conditions, TNF-α release was also evidenced in response 
to cold ischemia-reperfusion insult. 
IGF-1 supplementation prevented the release of TNF-α[46], 
which has a pivotal role in the progression of  liver reperfu-
sion damage. This finding is consistent with the accumulating 
evidence of  crosstalk between IGF-1 and TNF-α during 
ischemia reperfusion injury[47]. NO generated by IGF-1 could 
decrease TNF-α release, as occurs in liver ischemic precondi-
tioning, in which the induced hepatoprotection is also mediat-
ed by the inhibitory action of  NO on TNF-α release through 
eNOS activation[48]. 
In addition, several intracellular signalling pathways, 
including the extracellular signal-regulated kinases 1/2 and 
P38 mitogen-activated protein kinase, are activated during 
hypothermia[49-52], In these conditions, a mutual activation 
effect between TNF-α and MAPKs may also occur thus 
exacerbating the liver damage[53]. Our results indicate that 
cold storage in IGL-1® solution alone activates P38 and 
ERK 1/2, and that IGF-1 addition prevented this activa-
tion, which is consistent with a TNF-α reduction that 
leads to an improvement in liver injury and function. This 
is in line with previous reports that the addition of  TF to 
UW improved endothelial cell preservation by reducing 
ERK 1/2 and P38 activation[22]. 
In conclusion, we have demonstrated that IGF-1 ad-
dition to IGL-1® solution protects fatty liver against cold 
IRI. The beneficial action of  IGF-1 appears to be mediated 
by AKT activation and NO generation, with concomitant 
prevention of  pro-inflammatory cytokines, such as TNF-α. 
However, further studies will be required to examine the 
underlying mechanisms. This may increase the use of  stea-
totic livers, which partially compensates the shortage of  
organs for transplant.
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Background
Static preservation solution is crucial for graft viability; especially when steato-
sis is present. Serum-free preservation solutions deprive the donor organ of 
essential trophic factors such as insulin like growth factor-1 (IGF-1) which is as-
sociated with deleterious effects including cell cycle arrest and death. The ad-
dition of IGF-1 to University of Wisconsin (UW) solution improves the capacity 
of this preservation solution for protecting liver grafts subjected to a prolonged 
ischemic period. Serum-free institut georges lopez-1 (IGL-1) solution has been 
proposed as an effective alternative to UW for steatotic liver preservation.
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Research frontiers
In this study, the authors focused on the importance of IGF-1 as a biological ad-
ditive to IGL-1 preservation solution. The induction of nitric oxide (NO) synthesis 
by the modified IGL-1 solution improves microcirculatory disorders in fatty livers. 
IGL-1 supplementation with IGF-1 increases graft protection against ischemia 
reperfusion injury through the activation of protein kinase AKT and a concomitant 
reduction in tumour necrosis factor (TNF) release and P38/ERK 1/2 MAPKs acti-
vation which play an important cryoprotective role in liver graft preservation. 
Innovations and breakthroughs
The enrichment of IGL-1 solution with IGF-1 increases NO generation through 
AKT activation and prevents pro-inflammatory cytokine release such as TNF-α 
during steatotic liver graft reperfusion.
Applications 
The use of modified IGL-1 solutions should be a useful strategy for increasing 
steatotic liver graft preservation.
Peer review
This manuscript describes the beneficial effects of IGF-1 when added to IGL-1 
solution in the preservation of (fatty) liver.
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